Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice
Estrogen deficiency synergizes with metabolic dysfunction to aggravate metabolic dysfunction-associated steatotic liver disease progression through AMPK/mTOR pathway dysregulation. Tzp demonstrates comprehensive hepatoprotective effects, ameliorating steatosis, inflammation, and fibrosis while restoring metabolic homeostasis in this model of postmenopausal liver disease.
Authors
- Ilitch Aquino Marcondes‐de‐Castro (ORCID: https://orcid.org/0000-0003-3104-4033)
- Thatiany de Souza Marinho (ORCID: https://orcid.org/0000-0001-9976-9466)
- Carlos Alberto Mandarim‐de‐Lacerda (ORCID: https://orcid.org/0000-0003-4134-7978)
- Márcia Barbosa Águila (ORCID: https://orcid.org/0000-0003-3994-4589)
Institutions
- Universidade do Estado do Rio de Janeiro (BR)
- Artistic Realization Technologies (US)
Publication Details
- Journal
- Menopause The Journal of The North American Menopause Society
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1097/gme.0000000000002683
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71